We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

80 hedge funds and large institutions have $242M invested in TScan Therapeutics in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 16

36% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 14

21% more funds holding

Funds holding: 66 → 80 (+14)

6.67% more ownership

Funds ownership: 78.64% → 85.31% (+6.7%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

11% less capital invested

Capital invested by funds: $272M → $242M (-$29.9M)

Holders
80
Holders Change
+14
Holders Change %
+21.21%
% of All Funds
1.16%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
31
Increased
19
Reduced
14
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$21.8M
2
GPP
Great Point Partners
Connecticut
+$7.41M
3
SC
Stempoint Capital
New York
+$6.66M
4
LP
LMR Partners
United Kingdom
+$5.24M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.94M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$2.87M
2
LCM
Laurion Capital Management
New York
-$2.38M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.37M
4
Goldman Sachs
Goldman Sachs
New York
-$1.77M
5
Citigroup
Citigroup
New York
-$854K
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
1
Lynx1 Capital Management
Puerto Rico
$30.6M – – –
EC
2
EcoR1 Capital
California
$29.3M – – –
BlackRock
3
BlackRock
New York
$26.1M +$21.8M +2,763,139 +163%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$25.7M +$3.94M +500,000 +13%
BI
5
BVF Inc
California
$17.5M – – –
BBA
6
Baker Bros. Advisors
New York
$16.3M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$12.5M +$2.56M +325,461 +18%
PBM
8
Propel Bio Management
California
$12.2M – – –
DMC
9
Deer Management Company
New York
$7.29M – – –
AI
10
Alphabet Inc
California
$6.3M – – –
SAM
11
Simplify Asset Management
Nevada
$6.12M – – –
GPP
12
Great Point Partners
Connecticut
$5.5M +$7.41M +940,831 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$5.27M +$3.83M +486,720 +118%
SC
14
Stempoint Capital
New York
$4.94M +$6.66M +845,069 New
LP
15
LMR Partners
United Kingdom
$3.89M +$5.24M +665,529 New
DF
16
DC Funds
Virginia
$3.69M – – –
State Street
17
State Street
Massachusetts
$3.56M +$3.73M +473,085 +350%
Invesco
18
Invesco
Georgia
$2.92M +$90.3K +11,459 +2%
PBA
19
Paradigm Biocapital Advisors
New York
$2.07M +$2.79M +353,886 New
Marshall Wace
20
Marshall Wace
United Kingdom
$1.8M +$916K +116,316 +61%
Aberdeen Group
21
Aberdeen Group
United Kingdom
$1.71M +$726K +92,144 +46%
Morgan Stanley
22
Morgan Stanley
New York
$1.41M +$140K +17,778 +8%
TAM
23
Tocqueville Asset Management
New York
$1.23M -$18.7K -2,370 -1%
WP
24
Woodline Partners
California
$956K +$1.29M +163,492 New
Citadel Advisors
25
Citadel Advisors
Florida
$924K +$1.15M +146,531 +1,282%
1
2 3 4

TCRX Hedge Fund Activity: Q2 2024 in Review

80 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q2 2024, worth a combined $242M — down 11% from $272M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new TCRX positions and 16 closed out — a net gain of 15 holders — while 19 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $21.8M. The largest seller was Millennium Management, cutting an estimated $2.87M.

  • 80 institutional investors held TScan Therapeutics (TCRX) as of Q2 2024, up from 66 in Q1 2024.
  • Funds reported $242M of TScan Therapeutics stock for Q2 2024, down 11% quarter-over-quarter.
  • 31 funds opened new TScan Therapeutics positions in Q2 2024 and 16 closed out, a net change of +15 holders.
  • The largest TScan Therapeutics buyer in Q2 2024 was BlackRock, an estimated $21.8M added.
  • The largest TScan Therapeutics seller in Q2 2024 was Millennium Management, an estimated $2.87M sold.

Based on aggregated 13F filings for Q2 2024.